Cas no 149-64-4 (Scopolamine butylbromide)
Scopolamine butylbromide Chemical and Physical Properties
Names and Identifiers
-
- (-)scopolamine N-butyl bromide
- Scopolamine Butylbromide
- N-butylhyoscinium bromide
- hyoscine butylobromide
- Hyoscine-N-Butyl Bromide
- Scopolamine (butylbromide)
- (-)-SCOPOLAMINE N-BUTYL BROMIDE BP2002
- Hyoscine butylbromide
- N-Butylscopolammonium Bromide
- (-)-Scopolamine butylbromide
- (?)-N-Butylscopolamine bromide (?)-Scopolamine N-butyl bromide Hyoscine N-butyl bromide
- Butylscopolamine bromide
- Butylscopolammonium bromide
- (?)-N-Butylscopolamine bromide
- (?)-Scopolamine N-butyl bromide
- Hyoscine N-butyl bromide
- (-)-N-Butylscopolamine bromide
- buscol
- scobro
- donopon
- joscine
- scobron
- Stibron
- amisepan
- BUTYLMIN
- buscopan
- monospan
- Butylhyoscine
- Sporamin
- Scopolamine bromobutylate
- Buscolysin
- Buscolysine
- Buscolamin
- Tirantil
- Stilbron
- Buscapine
- Sparicon
- Scobutyl
- Buscapina
- Scopolan
- Scobutil
- MLS000069755
- 0GH9JX37C8
- Hyoscine butobromide
- Hyoscine butyl bromide
- Scopolamine but
- 3-Oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, (7(S)-(1alpha,2beta,4beta,5alpha,7beta))-
- HMS3714I19
- (1R,2R,4S,5S,7S)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane bromide
- AS-78017
- Hyoscin-N-butylbromid
- butylscopolamin
- HMS2235K20
- MLS006013629
- NCGC00186628-02
- Buscogast
- Scopinal
- HYOSCINE BUTYLBROMIDE [WHO-DD]
- MFCD00078561
- HYOSCINE BUTYLBROMIDE [MART.]
- Hyocimax
- CHEBI:32123
- SMR000058795
- HybroCare
- N-Butylscopolamine bromide
- (-)-SCOPOLAMINE N-BUTYL BROMIDE
- Spasler-P
- Scopolamine butyl bromide
- Hyoscin-N-butyl bromide
- Scopolamine N-n-butylbromide
- SMR004705104
- NS00079272
- HYOSCINE BUTYLBROMIDE [EP MONOGRAPH]
- 1-alpha-H,5-alpha-H-Tropanium, 8-butyl-6-beta,7-beta-epoxy-3-alpha-hydroxy-, bromide, (-)-tropate
- Hyoscine butylbromide; (-)-Scopolamine butylbromide; Butylscopolamine bromide
- A884250
- DTXCID102718
- hyoscin butobromide
- (1R,2R,4S,5S,7R)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0,2,4]nonan-9-ium bromide
- Tox21_112031
- CHEMBL1256901
- UNII-0GH9JX37C8
- SR-01000759230-3
- Opera_ID_556
- Hyoscine butylbromide, British Pharmacopoeia (BP) Reference Standard
- Butylscopolamine bromide [JAN]
- J-008603
- DTXSID1022718
- N-BUTYLSCOPOLAMMONIUM BROMIDE [MI]
- (2R,4S,5S,7s)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0(2,4)]nonane bromide
- Scopolamine butobromide
- Antipan
- 150521-07-6
- BUTYLSCOPOLAMINE BROMIDE [GREEN BOOK]
- SCHEMBL25291
- N-Butylscopolaminium bromide
- PD087140
- CCG-208412
- Buskolamin
- SCOPOLAMINE BUTYLBROMIDE [JAN]
- Scoburen
- CS-3142
- N-Butylhyoscine bromide
- AKOS037515799
- EINECS 205-744-1
- SR-01000759230
- 9-epi-Hyoscine Butylbromide
- Spasmin
- Hyoscine butylbromide, European Pharmacopoeia (EP) Reference Standard
- HMS3884J15
- AC-34139
- MLS002153372
- Tox21_112031_1
- F17660
- (-)-Scopolamine-N-butylbromide
- 3-OXA-9-AZONIATRICYCLO(3.3.1.0 SUP(2,4))NONANE, 9-BUTYL-7-((2S)-3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9-METHYL-, BROMIDE (1:1),(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-
- [(1S,2S,4R,5R)-9-butyl-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate;bromide
- Hyoscin-N-butylbromid [German]
- EN300-7394481
- AKOS016009548
- 149-64-4
- HY-N0340
- (-)-Scopolamine N-butyl bromide, >=98% (TLC), powder
- CAS-149-64-4
- Scopolamine N-butyl bromide
- scopolamine n-butylbromide
- NCGC00163224-01
- 9-epi-Hyoscine Butylbromide; 3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, stereoisomer (9CI); 3-Oxa-9-azatricyclo[3.3.1.02,4]nonane, 3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane deriv.; (1R,2R,4S,5S,7s,9s)-9-butyl-7-[[(2S)-3-hy
- HOZOZZFCZRXYEK-GSWUYBTGSA-M
- Butylscopolamine bromide [WHO-DD]
- HOZOZZFCZRXYEK-HNHWXVNLSA-M
- Scopolamine butylbromide
-
- MDL： MFCD00078561
- Inchi： 1S/C21H30NO4.BrH/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14;/h5-9,15-20,23H,3-4,10-13H2,1-2H3;1H/q+1;/p-1/t15?,16-,17-,18+,19-,20+,22?;/m1./s1
- InChI Key： HOZOZZFCZRXYEK-HNHWXVNLSA-M
- SMILES： [Br-].O1[C@@H]2[C@H]1[C@H]1CC(C[C@@H]2[N+]1(C)CCCC)OC([C@@H](C1C=CC=CC=1)CO)=O
Computed Properties
- Exact Mass: 439.13600
- Monoisotopic Mass: 439.13582 g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 27
- Rotatable Bond Count: 8
- Complexity: 500
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 3
- Undefined Atom Stereocenter Count : 2
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 59.1
- Surface Charge: 0
- Molecular Weight: 440.4
Experimental Properties
- Color/Form: Powder
- Melting Point: 142-1440C
- Boiling Point: °Cat760mmHg
- Flash Point: °C
- Solubility: H2O: 50?mg/mL
- PSA: 59.06000
- LogP: -0.80420
- Solubility: It is easily soluble in chloroform and water, and slightly soluble in ethanol.
- Specific Rotation: D20 -20.8° (c = 3 in water)
Scopolamine butylbromide Security Information
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P280-P305+P351+P338
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： R22: harmful if swallowed.
- RTECS：YM3500000
-
Hazardous Material Identification：
- Safety Term：6.1
- Packing Group：III
- Risk Phrases：R22
- Toxicity：LD50 in mice (mg/kg): 15.6 i.v.; 74 i.p.; 570 s.c.; 3000 orally (Stockhaus, Wick)
- Storage Condition：2-8°C
- Packing Group：III
- Hazard Level：6.1
Scopolamine butylbromide Customs Data
- HS CODE：2939999090
- Customs Data：
China Customs Code:
2934999090Overview:
2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Scopolamine butylbromide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI | BZP0706-20mg |
Scopolamine butylbromide |
149-64-4 | HPLC≥98% | 20mg |
￥260元 | 2023-09-15 | |
| DC Chemicals | DCD-046-20 mg |
Scopolamine butylbromide |
149-64-4 | >98%, Standard References Grade | 20mg |
$280.0 | 2022-02-28 | |
| TRC | B693750-50mg |
N-Butylscopolammonium Bromide |
149-64-4 | 50mg |
$ 63.00 | 2023-09-08 | ||
| TRC | B693750-1g |
N-Butylscopolammonium Bromide |
149-64-4 | 1g |
$ 68.00 | 2023-09-08 | ||
| TRC | B693750-5g |
N-Butylscopolammonium Bromide |
149-64-4 | 5g |
$ 148.00 | 2023-09-08 | ||
| TRC | B693750-10g |
N-Butylscopolammonium Bromide |
149-64-4 | 10g |
$ 283.00 | 2023-04-18 | ||
| TRC | B693750-25g |
N-Butylscopolammonium Bromide |
149-64-4 | 25g |
$ 707.00 | 2023-04-18 | ||
| TRC | B693750-50g |
N-Butylscopolammonium Bromide |
149-64-4 | 50g |
$ 1267.00 | 2023-04-18 | ||
| S e l l e c k ZHONG GUO | S2378-25mg |
Butylscopolamine Bromide |
149-64-4 | 99.99% | 25mg |
￥1040.79 | 2023-09-15 | |
| SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd. | N856419-1g |
N-Butylscopolammonium Bromide |
149-64-4 | 98% | 1g |
￥1,399.00 | 2022-09-01 |
Scopolamine butylbromide Suppliers
Audited Supplier
Scopolamine butylbromide Related Literature
-
Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
-
Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
-
Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
-
Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
-
Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
Related Categories
- Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Hydroxy acids and derivatives Beta hydroxy acids and derivatives
- Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Reference Substances
- Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
- Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients
Additional information on Scopolamine butylbromide
Scopolamine butylbromide: A Comprehensive Overview
Scopolamine butylbromide, with the chemical formula C17H23NO3B, is a well-established compound in the field of pharmaceuticals and neurology. Its CAS number, CAS no. 149-64-4, identifies it as a specific chemical entity with distinct properties and applications. This compound is primarily recognized for its pharmacological effects, particularly its role as an anticholinergic agent. The introduction of this compound into medical practice has been instrumental in managing various neurological and gastrointestinal conditions.
The primary pharmacological action of scopolamine butylbromide stems from its ability to block muscarinic acetylcholine receptors. This mechanism of action makes it highly effective in treating symptoms associated with conditions like motion sickness, where excessive acetylcholine activity contributes to nausea and vomiting. Furthermore, scopolamine butylbromide has been utilized in the management of conditions such as irritable bowel syndrome (IBS) and urinary incontinence, where modulation of cholinergic pathways is beneficial.
In recent years, research into scopolamine butylbromide has expanded beyond its traditional applications. Studies have begun to explore its potential in treating chronic pain conditions, particularly neuropathic pain. The compound's ability to modulate neurotransmitter activity has led researchers to investigate its efficacy in reducing pain signals transmitted through cholinergic pathways. Preliminary findings suggest that scopolamine butylbromide may offer significant relief for patients suffering from conditions like fibromyalgia and neuropathy.
Another area of interest has been the use of scopolamine butylbromide in cognitive enhancement. Research indicates that by reducing excessive cholinergic activity in certain brain regions, the compound may improve focus and cognitive function. This has led to exploratory studies involving patients with attention deficit hyperactivity disorder (ADHD) and age-related cognitive decline. While more research is needed to fully understand these potential applications, the preliminary results are promising.
The synthesis and chemical properties of scopolamine butylbromide have also been subjects of detailed study. The compound's structure allows for various modifications that can enhance its pharmacological profile. Researchers have been experimenting with different derivatives to improve bioavailability, reduce side effects, and extend the duration of action. These efforts are part of a broader trend in pharmaceutical chemistry aimed at developing more effective and targeted therapies.
One notable advancement in the field has been the development of transdermal formulations of scopolamine butylbromide. These formulations have shown promise in providing sustained release of the active compound, thereby reducing the frequency of administration required. This innovation has not only improved patient compliance but also minimized systemic side effects associated with oral administration. The development of such targeted delivery systems highlights the ongoing efforts to optimize therapeutic outcomes.
The safety profile of scopolamine butylbromide is another critical aspect that has been extensively studied. While generally well-tolerated, the compound can cause side effects such as dry mouth, blurred vision, and dizziness. These effects are primarily due to its anticholinergic properties and are more pronounced in elderly patients or those with pre-existing conditions like glaucoma or urinary retention. Careful monitoring and dose adjustment are essential to mitigate these risks.
In conclusion, scopolamine butylbromide remains a vital compound in modern medicine, with applications ranging from motion sickness to chronic pain management. The ongoing research into its pharmacological mechanisms and potential new uses underscores its importance in both clinical practice and academic study. As our understanding of neurotransmitter systems continues to evolve, it is likely that scopolamine butylbromide will continue to play a significant role in therapeutic interventions.
149-64-4 (Scopolamine butylbromide) Related Products
- 51-34-3(Scopolamine)
- 51-55-8(Atropine)
- 5027-68-9(O-Acetyl-(-)-norscopolamine)
- 4684-28-0(Nor Scopolamine)
- 77-23-6(pentoxyverine)
- 87-00-3((1R,3R,5S)-8-methyl-8-azabicyclo3.2.1octan-3-yl 2-hydroxy-2-phenylacetate)
- 1264-62-6(Erythromycin ethylsuccinate)
- 138-12-5(Atroscine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
